Radius Health Inc. Daily Stock Analysis

Daily Stock Analysis, RDUS, Radius Health Inc, priceseries

Radius Health Inc. Daily Stock Analysis
Stock Information
Open
8.37
Close
8.39
High
8.78
Low
8.08
Previous Close
8.51
Daily Price Gain
-0.12
YTD High
8.98
YTD High Date
Mar 2, 2022
YTD Low
5.92
YTD Low Date
Jan 18, 2022
YTD Price Change
1.46
YTD Gain
21.07%
52 Week High
26.16
52 Week High Date
Mar 23, 2021
52 Week Low
5.92
52 Week Low Date
Jan 18, 2022
52 Week Price Change
-12.09
52 Week Gain
-59.03%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 4. 2017
39.85
Jan 17. 2017
43.14
8 Trading Days
8.27%
Link
LONG
Jun 12. 2017
38.91
Jul 10. 2017
45.77
19 Trading Days
17.63%
Link
LONG
Sep 22. 2017
35.17
Oct 9. 2017
38.21
11 Trading Days
8.63%
Link
LONG
Dec 28. 2017
31.52
Jan 16. 2018
34.40
11 Trading Days
9.13%
Link
LONG
Dec 28. 2018
14.84
Jan 11. 2019
16.46
9 Trading Days
10.93%
Link
LONG
Mar 28. 2019
19.10
Apr 18. 2019
21.53
15 Trading Days
12.73%
Link
LONG
Jun 13. 2019
21.78
Jun 25. 2019
23.21
8 Trading Days
6.57%
Link
LONG
Aug 6. 2019
21.54
Sep 23. 2019
27.77
33 Trading Days
28.94%
Link
LONG
Oct 14. 2019
25.05
Nov 4. 2019
28.35
15 Trading Days
13.18%
Link
LONG
Apr 16. 2020
13.84
Apr 29. 2020
15.20
9 Trading Days
9.80%
Link
LONG
Oct 5. 2020
12.18
Oct 22. 2020
12.93
13 Trading Days
6.16%
Link
LONG
Nov 10. 2020
14.86
Nov 30. 2020
15.86
13 Trading Days
6.70%
Link
LONG
Dec 14. 2020
14.71
Dec 31. 2020
18.12
12 Trading Days
23.16%
Link
LONG
Jan 5. 2021
18.66
Jan 25. 2021
21.08
13 Trading Days
12.97%
Link
LONG
Apr 22. 2021
20.02
May 4. 2021
21.08
8 Trading Days
5.27%
Link
LONG
Oct 7. 2021
13.01
Nov 8. 2021
20.36
22 Trading Days
56.51%
Link
Company Information
Stock Symbol
RDUS
Exchange
NasdaqGM
Company URL
http://www.radiuspharm.com
Company Phone
617-551-4000
CEO
Robert E. Ward
Headquarters
Massachusetts
Business Address
ATTN: CHIEF FINANCIAL OFFICER, 950 WINTER STREET, WALTHAM, MA 02451
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001428522
About

Radius Health, Inc. a biopharmaceutical company, which engages in the discovery and development of therapeutics for the treatment of osteoporosis and other women health conditions. Its BA058 Injection product is a daily subcutaneous injection of novel synthetic peptide analog of human parathyroid hormone-related protein. The company also develops BA058 Microneedle Patch; RAD1901, a selective estrogen receptor modulator for the treatment of vasomotor symptoms in women entering menopause; and RAD140, a selective androgen receptor modulator. Its initial business was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt and John T. Potts on October 3, 2003. Radius Health was founded on February 4, 2008 and is headquartered in Cambridge, MA.

Description

Radius Health, Inc., a biopharmaceutical company, develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the United States. Its product candidates include Abaloparatide-SC, an injectable subcutaneous formulation of abaloparatide, which has completed Phase III clinical trial for the treatment of patients with postmenopausal osteoporosis; and Abaloparatide-TD, a transdermal patch for use as a short wear-time transdermal patch. The company is also involved in developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer, as well as in Phase IIb clinical trial for the treatment of postmenopausal vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator for the treatment of breast cancer. It has collaborations and license agreements with 3M; Ipsen Pharma SAS; Eisai Co. Ltd.; Lonza Group Ltd.; Novartis Pharmaceuticals; and Takeda Pharmaceutical Company Limited, as well as research and development agreements with Nordic Bioscience Clinical Development VII A/S. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading